CGTLive Staff
Articles
Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP
May 10th 2022Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial (NCT04372706) with solid tumors, presented recently at the 2022 AACR Annual Meeting.
Opportunities for CAR T-Cell Therapy in Solid Tumors
May 6th 2022Radek Špíšek, PhD, co-founder and chief executive officer of SOTIO Global, and Geoffrey Hodge, chief executive officer of SOTIO BioTech US, join CGTL to discuss its 3 technology platforms and how they are leveraging them to attack the solid tumor micro-environment.
Keeping Patients at the Center of CAR T-Cell Therapy Development: Jennifer Chow
April 29th 2022The CEO and managing director of Chimeric Therapeutics hopes to contribute to the narrative with a handful of offerings in development across 2 platforms: CORE-NK, which uses allogeneic natural killer cells, and T-cell derived autologous therapies.
Leveraging the Capabilities of Gamma Delta T Cells: Sebastian Wanless, MD, PhD
April 22nd 2022Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.
Pushing for a New Era in Cardiology: Matt Killeen, PhD
April 20th 2022Matt Killeen, PhD, chief scientific officer at Renovacor, shares updates on the company's lead candidate, REN-001, an adeno-associated viral vector serotype 9-based gene therapy for the treatment of BAG3-associated dilated cardiomyopathy.
TCR Search-and-Capture: Working Toward Personalized Cancer Therapy
April 18th 2022David Apelian, MD, PhD, MBA, chief executive officer at BlueSphere Bio; and Warren Shlomchik, MD, cofounder and scientific advisory board chairman at BlueSphere Bio, join CGTL to discuss the company's leading T-cell therapy clinical program.
